DEF 14A: Avanos Medical Announces Details for 2024 Annual Stockholders Meeting

Avanos Medical has set the date for its 2024 Annual Meeting of Stockholders on April 25, 2024, and released related proxy materials.

Summary

• Avanos Medical, Inc. will hold its 2024 Annual Meeting of Stockholders on April 25, 2024, at 9:00 a.m. Eastern Time at the company's headquarters in Alpharetta, Georgia.
• Stockholders of record as of March 1, 2024, are entitled to notice of and to vote at the meeting.
• The agenda includes the election of five directors, ratification of the appointment of Deloitte & Touche LLP as independent auditors for 2024, and an advisory vote on executive compensation.
• The Board of Directors recommends voting 'FOR' all director nominees and 'FOR' the ratification of auditors and the advisory vote on executive compensation.
• Proxy materials are available online at www.proxyvote.com and were first distributed to stockholders on March 15, 2024.

Sentiment

Score: 7

Explanation: The document is primarily informational, but the Board's recommendations and the CEO's positive comments suggest a moderately positive outlook.

Positives

• The Board of Directors is recommending a vote 'FOR' all proposals, indicating confidence in the company's direction and management.
• The company provides multiple avenues for stockholders to vote, including online, by phone, and by mail, ensuring accessibility for all stockholders.
• Avanos is committed to helping reduce and eliminate opioid abuse by offering alternate methods of pain relief.

Negatives

• John P. Byrnes, a director since 2014, is not up for re-election, creating a vacancy on the Board.
• The company has commenced a search for another independent individual to fill such vacancy.

Risks

• If stockholders fail to ratify the appointment of Deloitte, the Audit Committee may choose to retain Deloitte or select a different independent auditor.
• The say-on-pay vote is advisory and non-binding, meaning the Board is not obligated to act on the results, although they will consider stockholder concerns.

Future Outlook

The company anticipates that the transformation initiative will ultimately result in gross savings of between $45 and $55 million compared to 2022 by 2025.

Management Comments

• Joseph F. Woody, our CEO, stated when announcing our Fourth Quarter and Full-Year 2023 results: 'We were very pleased with the overall execution on our transformation initiative last year, which sets the foundation for more profitable growth in 2024 and for reaching our mid-term financial targets in 2025.'
• Joseph F. Woody, our CEO, stated when announcing our Fourth Quarter and Full-Year 2023 results: 'We believe we are poised to maintain the positive momentum in our Digestive Health portfolio and we are also confident that our strategy for the Pain Management and Recovery business will lead to sustainable growth as we enter 2024.'

Industry Context

The document highlights Avanos's commitment to non-opioid pain therapies, aligning with the broader healthcare industry's focus on reducing opioid usage and finding alternative pain management solutions.

Comparison to Industry Standards

• The peer group used for executive compensation benchmarking includes companies like Abiomed, Globus Medical, and Integra LifeSciences, suggesting Avanos aims to align its compensation practices with industry leaders in the medical technology space.
• The company's ESG initiatives, such as reducing waste and GHG emissions, are in line with increasing industry focus on sustainability and corporate responsibility.
• Avanos's commitment to diversity, equity, and inclusion (DE&I) aligns with broader industry trends towards creating more inclusive and equitable workplaces.

Stakeholder Impact

• Shareholders are directly impacted through voting on key company decisions.
• Employees are affected by executive compensation policies and DE&I initiatives.
• Patients benefit from the company's focus on clinically superior medical device solutions and alternative pain relief methods.

Next Steps

• Stockholders are urged to vote their shares as soon as possible.
• The Board intends to identify an independent individual to fill the vacancy created by the departure of John P. Byrnes.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Deloitte & Touche LLP, Executive Compensation, Director Election, Avanos Medical